Stopped: Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study
Timeframe: From Entry Visit to End of Safety Follow-Up Visit (up to 5 years)
75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month 0-3)
75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >3-6)
75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >6-9)
75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >9-12)
75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >12-15)
75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >15-18)
75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >18-21)
75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >21-24)
75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >24-27)
75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >27-30)
75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >30-33)
75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >33-36)
75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >36-39)
75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >39-42)
75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >42-45)
75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >45-48)
75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >48-51)
75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >51-54)
75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period
Timeframe: Over 3-month interval over the Evaluation Period (Month >54-57)